08:58 AM EDT, 07/17/2024 (MT Newswires) -- InMode ( INMD ) said Wednesday it has received an additional US Food and Drug Administration's clearance for Morpheus8, a fractional radiofrequency microneedling technology for soft tissue contraction.

The regulator cleared the Morpheus8 applicators for fractional radiofrequency use in dermatologic skin procedures where coagulation/contraction of soft tissue or hemostasis is required, the medical technologies firm added.

InMode ( INMD ) has rolled out IgniteRF and OptimasMAX platforms, which include the Morpheus8 family of handpieces, it said.

Price: 18.75, Change: -0.31, Percent Change: -1.63